CORCEPT THERAPEUTICS INC Operating Lease, Expense
CORCEPT THERAPEUTICS INC (CORT) reported Operating Lease, Expense of $700.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-10-30
- CORCEPT THERAPEUTICS INC operating lease, expense for the quarter ending 2024-09-30 was $700.00K, a 16.67% increase year-over-year.
- CORCEPT THERAPEUTICS INC operating lease, expense for the quarter ending 2024-06-30 was $800.00K, a 33.33% increase year-over-year.
- CORCEPT THERAPEUTICS INC operating lease, expense for the quarter ending 2024-03-31 was $600.00K, a 0.00% change year-over-year.
- CORCEPT THERAPEUTICS INC operating lease, expense for the quarter ending 2023-12-31 was $600.00K, a 0.00% change year-over-year.
- CORCEPT THERAPEUTICS INC operating lease, expense for fiscal 2023 was $2.40M, a 4.35% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC operating lease, expense for fiscal 2022 was $2.30M, a 9.52% increase from fiscal 2021.
- CORCEPT THERAPEUTICS INC operating lease, expense for fiscal 2021 was $2.10M, a 10.53% increase from fiscal 2020.
- CORCEPT THERAPEUTICS INC operating lease, expense for fiscal 2020 was $1.90M, a 26.67% increase from fiscal 2019.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $700.00K 10-Q · filed 2024-10-30 | $1.50M derived: sum of 2 quarters · filed 2024-10-30 | $2.10M 10-Q · filed 2024-10-30 | $2.70M derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-06-30 | $800.00K 10-Q · filed 2024-07-29 | $1.40M 10-Q · filed 2024-07-29 | $2.00M derived: sum of 3 quarters · filed 2024-07-29 | $2.60M derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-03-31 | $600.00K 10-Q · filed 2024-05-01 | $1.20M derived: sum of 2 quarters · filed 2024-05-01 | $1.80M derived: sum of 3 quarters · filed 2024-10-30 | $2.40M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.20M derived: sum of 2 quarters · filed 2024-10-30 | $1.80M derived: sum of 3 quarters · filed 2024-10-30 | $2.40M 10-K · filed 2024-02-15 |
| 2023-09-30 | $600.00K 10-Q · filed 2024-10-30 | $1.20M derived: sum of 2 quarters · filed 2024-10-30 | $1.80M 10-Q · filed 2024-10-30 | $2.40M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-06-30 | $600.00K 10-Q · filed 2024-07-29 | $1.20M 10-Q · filed 2024-07-29 | $1.80M derived: sum of 3 quarters · filed 2024-07-29 | $2.40M derived: sum of 4 quarters · filed 2024-07-29 |
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-01 | $1.20M derived: sum of 2 quarters · filed 2024-05-01 | $1.80M derived: sum of 3 quarters · filed 2024-05-01 | $2.40M derived: sum of 4 quarters · filed 2024-05-01 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.20M derived: sum of 2 quarters · filed 2024-02-15 | $1.80M derived: sum of 3 quarters · filed 2024-02-15 | $2.30M 10-K · filed 2024-02-15 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-01 | $1.20M derived: sum of 2 quarters · filed 2023-11-01 | $1.70M 10-Q · filed 2023-11-01 | $2.20M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-02 | $1.10M 10-Q · filed 2023-08-02 | $1.60M derived: sum of 3 quarters · filed 2024-02-15 | $2.10M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-03 | $1.00M derived: sum of 2 quarters · filed 2024-02-15 | $1.50M derived: sum of 3 quarters · filed 2024-02-15 | $2.00M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.00M derived: sum of 2 quarters · filed 2024-02-15 | $1.50M derived: sum of 3 quarters · filed 2024-02-15 | $2.10M 10-K · filed 2024-02-15 |
| 2021-09-30 | $500.00K 10-Q · filed 2022-11-03 | $1.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.60M 10-Q · filed 2022-11-03 | $2.10M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $500.00K 10-Q · filed 2022-08-04 | $1.00M 10-Q · filed 2022-08-04 | $1.60M derived: sum of 3 quarters · filed 2023-02-28 | $2.10M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $500.00K 10-Q · filed 2022-05-05 | $1.10M derived: sum of 2 quarters · filed 2023-02-28 | $1.60M derived: sum of 3 quarters · filed 2023-02-28 | $2.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.10M derived: sum of 2 quarters · filed 2023-02-28 | $1.50M derived: sum of 3 quarters · filed 2023-02-28 | $1.90M 10-K · filed 2023-02-28 |
| 2020-09-30 | $500.00K 10-Q · filed 2020-11-03 | $900.00K derived: sum of 2 quarters · filed 2020-11-03 | $1.30M 10-Q · filed 2020-11-03 | $1.70M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $400.00K 10-Q · filed 2020-08-04 | $800.00K 10-Q · filed 2020-08-04 | $1.20M derived: sum of 3 quarters · filed 2022-02-15 | $1.60M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $400.00K 10-Q · filed 2020-05-04 | $800.00K derived: sum of 2 quarters · filed 2022-02-15 | $1.20M derived: sum of 3 quarters · filed 2022-02-15 | $1.60M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $800.00K derived: sum of 2 quarters · filed 2022-02-15 | $1.20M derived: sum of 3 quarters · filed 2022-02-15 | $1.50M 10-K · filed 2022-02-15 |
| 2019-09-30 | $400.00K 10-Q · filed 2019-11-07 | $800.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.10M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $400.00K 10-Q · filed 2019-08-01 | $800.00K 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $400.00K 10-Q · filed 2020-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |